.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Recent breakthroughs in molecular biology emphasize the KIF15 therapeutic potential in modern medicine. KIF15 belongs to the kinesin-12 family of motor proteins. Primarily, it maintains the bipolar geometry of the mitotic spindle during cell division. Furthermore, researchers have identified KIF15 as a key factor in several human malignancies. Beyond cancer, genetic studies link KIF15 variants to chronic lung conditions like idiopathic pulmonary fibrosis.
Mechanistically, KIF15 drives several oncogenic processes across various solid tumors. It activates critical signaling pathways such as MEK-ERK and PI3K-AKT. Additionally, it helps cancer cells bypass resistance to Eg5 inhibitors. This adaptability makes it a dangerous driver of tumor progression. However, this same mechanism highlights the KIF15 therapeutic potential for combination therapies. For instance, using KIF15 inhibitors alongside standard treatments could improve patient outcomes.
In the context of respiratory health, KIF15 variants play a distinct role. Both rare and common genetic mutations can decrease protein expression in the lungs. Consequently, this reduction impairs the regenerative capacity of the lung epithelium. This process represents a non-telomerase pathway for pulmonary fibrosis development. Therefore, monitoring KIF15 levels could serve as a valuable diagnostic tool in the future.
KIF15 maintains the mitotic spindle and promotes tumor growth through signaling pathways like MEK-ERK. Moreover, it helps cells overcome drug resistance.
Yes, preclinical studies show that inhibiting KIF15 can restrict tumor progression. Researchers are currently exploring it as a candidate for combination anticancer strategies.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.
References
Xiang S et al. KIF15 (Kinesin-12): molecular biology, physiological functions, and roles in disease. J Cancer Res Clin Oncol. 2026 May 10. doi: 10.1007/s00432-026-06501-0. PMID: 42107035.
Zhang D et al. Rare and Common Variants in KIF15 Contribute to Genetic Risk of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2022 Jul 1;206(1):56-69. doi: 10.1164/rccm.202110-2439OC.
Wang J et al. Kinesin 12 (KIF15) contributes to the development and tumorigenicity of prostate cancer. Biochem Biophys Res Commun. 2021 Oct 22;576:7-14. doi: 10.1016/j.bbrc.2021.08.072.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A comprehensive review of KIF15's role in multiple malignancies, drug resistance mechanisms, and its link to idiopathic pulmonary fibrosis susceptibility....
4 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
